JoshuaOlajideAtibaMDMHA, FRCPC

PubMed

• 67 citations
  Single-Dose Administration of Bowman-Birk Inhibitor Concentrate in Patients with Oral Leukoplakia
  William B. Armstrong, Ann R. Kennedy, Wan Xs, Joshua O. Atiba, Christine E. McLaren
  Cancer Epidemiology, Biomarkers & Prevention. 2000-01-01
• 5 citations
  Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer : a Southwest Oncology Group study
  Joshua O. Atiba, Stephanie Green, Harry E. Hynes, C. Kent Osborne, Thomas P. Miller
  Investigational New Drugs. 1994-01-01
• 16 citations
  Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis.
  H Manzone, P C Billings, W N Cummings, R Feldman, Larry C. Clark
  Cancer Epidemiology, Biomarkers & Prevention. 1995-07-01

Books/Book Chapters

• High Risk Breast Cancer - Diagnosis. 
  Chapter: The Role of Fine Needle Aspiration in Determining the Risk of Breast Cancer. 
  Page 120 - 138Le Riche J, Atiba J, Ragaz J, DeJong GEditors: Ragaz J, Ariel I.Springer-Verlag, Berlin, Germany1989

Abstracts/Posters

• Retinoic acid (atRA): a new and effective salvage agent for recurrent high-grade malignant glioma (RHGMG).
  Atiba JO, Meyskens FL, Schell MJ, Armentrout SA, Cho J, Wong SF, Neal J, Ramsinghani N, Proc ASCO, 1/1/1996
• Alltransretinoic acid: preliminary evidence for efficacy in recurrent high grade malignant gliomas and effect of drug holiday versus alpha interferon therapy on restor...
  Atiba J, Meyskens Fl Jr., Schell MJ, Armentrout SA, Cho J, Wong SF, Thiruvengadam R, Manzardo A, Annal Oncol, 1/1/1996
• Restoration of oral all trans-retinoic acid (tRA) bioavailability: Combination therapy with alpha interferon (IFN) versus a drug holiday.
  Atiba JO, Manzardo AM, Schell M, Thiruvengadam R, Prestifilippo J and Lutzky J, Proc ASCO, 31st ASCO Annual Meeting, Los Angeles, CA, 5/21/1995
• Effect of drug holiday on all-trans retinoic acid pharmacokinetics.
  Atiba JO, Manzardo AM, Thiruvengadam R, Schell M, Clin Pharm Ther, 96th Annual Meeting of ASCPT, San Diego, CA, 3/15/1995
• Trans-Retinoic Acid (tRA) with chemotherapy in non-small cell lung cancer (NSCLC): a pilot phase II study.
  Thiruvengadam R, Atiba J, Azami S, Proc ASCO, 1/1/1995
• PALA plus 5-Fluorouracil (FU)/leucovorin (LV) in advanced gastric (G) and pancreatic (P) cancer.
  Nagourney RA, Baqai R, Atiba J, Iyer P, Ciarolla A, Blitzer J, Proc ASCO, 1/1/1994
• Transretinoic Acid (tRA) in the treatment of malignant gliomas (MG).
  Atiba J, Jamil S, Meyskens FL Jr, Cho J, Armentrout S, Berkson P, Wong S-F, Neal J, Proc ASCO, 1/1/1994
• Prognostic Markers as Predictor of drug response: In vitro correlations.
  Fruehauf JP, Atiba J, Eck L, Breast Rees Treat, 1/1/1993
• PALA plus 5-fluorouracil (5-FU)/Leucovorin (LU) in advanced gastric (G) and pancreatic (P) cancer.
  Nagourney RA, Atiba J, Ciarolla A, Blitzer J, Iyer P, Proc ASCO, 1/1/1993
• PALA plus 5-fluorouracil (5-FU) and low dose leucovorin (LD LV) in advanced gastric and pancreatic cancer: A Phase II trial.
  Nagourney RA, Eckerling G, Atiba JO, Iyer P, Proc Am Soc Clin Oncol, 1/1/1992
• Neupogen 7 (recombinant Met-Human-G-CSF) as an adjunct to CNF chemotherapy (cyclophosphamide, mitoxantrone, 5-fluorouracil) in advanced breast cancer
  Budd GT, Silver RT, Atiba JO, Presant C et al, Breast Cancer Research and Treatment, 1/1/1992
• Models for studying drug interaction in man.
  Atiba JO, UBC Residents Research Day, Vancouver, BC, 5/30/1990
• Role of fine needle aspiration (FNA) in risk assessment of breast cancer. Data from the British Columbia FNA flow cytometry pilot project.
  LeRiche J, Ragaz J, Atiba J, DeJong G, Proc Am Soc Clin Oncol, 1/1/1990
• Prognostic factors in node negative breast cancer (NNBC): Results from two British Columbia (BC) Cohorts.
  Atiba, JO, UBC Residents Research Day, Vancouver, BC, 5/24/1989
• Vessel invasion in node negative breast cancer (NNBC): A multivariate analysis.
  Coppin C, Atiba J, Worth A, Spinelli J, Proc Am Soc Clin Oncol, 25th annual meeting Am Soc Clinical Oncology, San Francisco, CA, 5/21/1989
• 10-year experience with cancer of unknown primary site (CUPS): Identifying long term survivors.
  Atiba J, Murray N, Coppin C, Brockington D, Proc Am Soc Clin Oncol, 1/1/1989
• Clinical significance of lymphatic, vascular or neural invasion (LVN+) in node-negative breast cancer (NNBC).
  Atiba J, Coppin C, Ragaz J, Worth A, Plenderleith I, Knowling M, Basco V, Proc Am Soc Clin Oncol, 24th annual meeting Am Soc Clinical Oncology, New Orleans, LA, 5/22/1988
• Effect of ketoconazole on Polymorphic 4-hydroxylation of S-Mephenytoin and debrisoquine.
  Atiba JO (MB), Blaschke TF (MD) and Wilkinson GR (PhD), Clin Pharm Ther, 89th Annual meeting of ASCPT, San Diego, CA, 3/9/1988
• Antipyrine clearance is decreased after etomidate anesthesia.
  Atiba JO, White PF, and Blaschke TF, Clinical Research, AFCR (Western Section) meeting, Carmel, CA, 2/16/1988
• Antipyrine half-life determination from Urine data.
  Atiba JO (MB), Taylor G (PhD), Blaschke TF (MD), Pershe RA (BS), and Brown M (RN), Clin Pharm Ther, 87th Annual meeting of ASCPT, Washington, DC, 3/20/1986
• Recombinant Beta ser-interferon inhibits antipyrine clearance in man.
  Blaschke TF, Horning SJ, Merigan TC, Gurley VF, Brown MI, and Atiba JO, Clinical Research, AFCR (Western Section) meeting, Carmel, CA, 2/6/1985
• Etomidate inhibits antipyrine metabolism in mice.
  Atiba JO and Blaschke TF, Clinical Research, AFCR (Western Section) meeting, Carmel, CA, 2/6/1985
• Join now to see all